T-TEER for Tricuspid Regurgitation Induces Reverse Remodeling, Works in Tricky Anatomies tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.
July 27, 2021
MIAMI, FL A debate at TVT 2021 last week was supposed to be about whether guideline-directed medical therapy should be tried at maximally tolerated doses before patients undergo transcatheter edge-to-edge repair (TEER) for functional mitral regurgitation (MR), but it ended up focusing on the difficulty of getting patients on foundational heart failure therapies in the first place.
JoAnn Lindenfeld, MD (Vanderbilt Heart and Vascular Institute, Nashville, TN), led off by arguing that drug therapy should be maxed out first, but her ostensible opponent didn’t disagree.
“I want to concede the debate to JoAnn. I think she made a convincing argument, and I really don’t have much to add to what she said,” Milton Packer, MD (Baylor Heart and Vascular Institute, Houston, TX), said.
December 15, 2020
Patients treated with the MitraClip (Abbott) at one of three European hospitals were more likely to survive and avoid rehospitalization if they fit a “COAPT-like profile” based on echocardiography parameters, researchers reported in
JACC: Cardiovascular Interventions last week.
According to lead author Marianna Adamo, MD (ASST Spedali Civili di Brescia, Italy), the findings shed light on patient prognosis following the percutaneous procedure as it relates to underlying COAPT criteria defined here as a lack of severe left ventricular (LV) impairment, hemodynamic instability, and right ventricular (RV) impairment and/or severe pulmonary hypertension.
“We wanted to dispel the concept of nonapplicability of these criteria in the real world,” Adamo told TCTMD in an email. Not only were more than two-thirds of the patients who’d been treated with the clip COAPT-like but “these patients had a significantly better outcome compared to non-COAPT-like ones,�